PBAC News Updates
Updated: Apr 4
20 October 2019
Vertex’s Symdeko and Orkambi is now reimbursed in Australia
Vertex’s Symdeko (tezacaftor/ivacaftor and ivacaftor) and Orkambi (lumacaftor/ivacaftor) are now reimbursed Australia.
Symdeko is approved in patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have one copy of the F508del mutation and another responsive residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Orkambi is now reimbursed in children with CF ages 2 to 5 who have two copies of the F508del mutation in the CFTR gene. The product already reimbursed for patients aged more than 6 years since October 2018.
The company in its press released mentioned that the product is reimbursed in seventeen countries.